GlobeNewswire Inc.··Telix Pharmaceuticals LimitedTelix's Zircaix Shows Promise Beyond Kidney Cancer Focus With 98% Accuracy Rate
Telix Pharmaceuticals' Zircaix achieved 98% accuracy in detecting both clear and non-clear cell kidney cancers in Phase 3 trials, expanding its clinical potential and market opportunity.
TLXradiopharmaceuticalsrenal cell carcinoma